#CombinationTherapy with SGLT-2 inhibitors and GLP-1 receptor agonists improves heart and #MetabolicOutcomes in type 2 #diabetes, reducing #HeartFailure #hospitalizations and major #CardiovascularEvents, with some increased GI side effects. #Diabetes dmsjournal.biomedcentral.com/articles/10....
Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of ran...
Background The potential benefits and risks of combination therapy with sodium-glucose co-transporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus monotherap...
dmsjournal.biomedcentral.com
July 21, 2025 at 6:11 AM
#CombinationTherapy with SGLT-2 inhibitors and GLP-1 receptor agonists improves heart and #MetabolicOutcomes in type 2 #diabetes, reducing #HeartFailure #hospitalizations and major #CardiovascularEvents, with some increased GI side effects. #Diabetes dmsjournal.biomedcentral.com/articles/10....
This study finds TGM2 elevated in #AcuteCoronarySyndrome & linked to #AcuteMyocardialInfarction, enhancing prognostic assessment for #CardiovascularEvents when combined with #Anatomical #RiskScores, underscoring its value in #RiskStratification.
Read more: tinyurl.com/2xlmnoxp
Read more: tinyurl.com/2xlmnoxp
May 29, 2026 at 1:47 PM
This study finds TGM2 elevated in #AcuteCoronarySyndrome & linked to #AcuteMyocardialInfarction, enhancing prognostic assessment for #CardiovascularEvents when combined with #Anatomical #RiskScores, underscoring its value in #RiskStratification.
Read more: tinyurl.com/2xlmnoxp
Read more: tinyurl.com/2xlmnoxp
Stopping or interrupting #GLP1Drugs for six months or more in #Type2Diabetes patients raises the risk of major #CardiovascularEvents by up to 22%, undoing previous benefits.
#GLP1 #GLP1Medications #CardiovascularRisk
#GLP1 #GLP1Medications #CardiovascularRisk
Stopping GLP-1 drugs can quickly erase cardiovascular benefits – BioNews Central
Stopping or interrupting GLP-1 drugs for six months or more in type 2 diabetes patients raises the risk of major cardiovascular events by up to 22%, undoing previous benefits. ...
sbee.link
March 18, 2026 at 7:24 PM
Stopping or interrupting #GLP1Drugs for six months or more in #Type2Diabetes patients raises the risk of major #CardiovascularEvents by up to 22%, undoing previous benefits.
#GLP1 #GLP1Medications #CardiovascularRisk
#GLP1 #GLP1Medications #CardiovascularRisk
An irregular ##SleepWakeCycle is associated with an increased risk of major ##CardiovascularEvents, such as ##HeartAttack and ##stroke, even among individuals who get the recommended amount of ##sleep each night.
##IrregularSleep ##CardiovascularDisease ##CardiovascularRisk
##IrregularSleep ##CardiovascularDisease ##CardiovascularRisk
Irregular sleep-wake cycle linked to heightened risk of major cardiovascular events – BioNews Central
An irregular sleep-wake cycle is associated with a heightened risk of major cardiovascular events, such as heart attack and stroke, even among individuals who get the recommended amount of sleep each night. ...
sbee.link
November 27, 2024 at 2:06 PM
An irregular ##SleepWakeCycle is associated with an increased risk of major ##CardiovascularEvents, such as ##HeartAttack and ##stroke, even among individuals who get the recommended amount of ##sleep each night.
##IrregularSleep ##CardiovascularDisease ##CardiovascularRisk
##IrregularSleep ##CardiovascularDisease ##CardiovascularRisk